ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ

$20.94

-$0.32 (1.53%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$20.84$21.47

Open $21.35

52 Week Range

$19.69$28.35

Previous Close $21.27

Market Cap3.59B

Volume1.19M

Avg Volume1.71M

P/E (TTM)9.65

EPS (TTM)$2.20

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for ACADIA Pharmaceuticals Inc.

MAY62026

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Source: Business Wire•41 days ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a...

APR302026

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.

Source: Business Wire•47 days ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Ac...

APR282026

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Source: Business Wire•49 days ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference Fireside Chat: Tuesday, May 12, 2026 at 4:20 p.m. Pacifi...

APR172026

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Source: Business Wire•61 days ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April...

APR152026

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Source: Business Wire•62 days ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will al...

APR72026

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

Source: Business Wire•71 days ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the...